Protein-gold clusters-capped mesoporous silica nanoparticles for high drug loading, autonomous gemcitabine/doxorubicin co-delivery, and in-vivo tumor imaging
AuthorsCroissant, Jonas G.
Alsaiari, Shahad K.
Zink, Jeffrey I.
Khashab, Niveen M.
KAUST DepartmentAdvanced Membranes and Porous Materials Research Center
Biological and Environmental Sciences and Engineering (BESE) Division
Chemical Science Program
Physical Science and Engineering (PSE) Division
Smart Hybrid Materials (SHMs) lab
Online Publication Date2016-03-23
Print Publication Date2016-05
Permanent link to this recordhttp://hdl.handle.net/10754/603622
MetadataShow full item record
AbstractFunctional nanocarriers capable of transporting high drug contents without premature leakage and to controllably deliver several drugs are needed for better cancer treatments. To address this clinical need, gold cluster bovine serum albumin (AuNC@BSA) nanogates were engineered on mesoporous silica nanoparticles (MSN) for high drug loadings and co-delivery of two different anticancer drugs. The first drug, gemcitabine (GEM, 40 wt%), was loaded in positively-charged ammonium-functionalized MSN (MSN-NH3+). The second drug, doxorubicin (DOX, 32 wt%), was bound with negatively-charged AuNC@BSA electrostatically-attached onto MSN-NH3+, affording highly loaded pH-responsive MSN-AuNC@BSA nanocarriers. The co-delivery of DOX and GEM was achieved for the first time via an inorganic nanocarrier, possessing a zero-premature leakage behavior as well as drug loading capacities seven times higher than polymersome NPs. Besides, unlike the majority of strategies used to cap the pores of MSN, AuNC@BSA nanogates are biotools and were applied for targeted red nuclear staining and in-vivo tumor imaging. The straightforward non-covalent combination of MSN and gold-protein cluster bioconjugates thus leads to a simple, yet multifunctional nanotheranostic for the next generation of cancer treatments.
CitationProtein-gold clusters-capped mesoporous silica nanoparticles for high drug loading, autonomous gemcitabine/doxorubicin co-delivery, and in-vivo tumor imaging 2016 Journal of Controlled Release
SponsorsThe authors gratefully acknowledge King Abdullah University of Science and Technology (KAUST) and the University of California, Los Angeles for the support of this work. NIH grant CA133697. Authors thank Dr. Chong H. Chang for the ICP-AES measurements.
JournalJournal of Controlled Release
- pH-sensitive Au-BSA-DOX-FA nanocomposites for combined CT imaging and targeted drug delivery.
- Authors: Huang H, Yang DP, Liu M, Wang X, Zhang Z, Zhou G, Liu W, Cao Y, Zhang WJ, Wang X
- Issue date: 2017
- A dual-sensitive mesoporous silica nanoparticle based drug carrier for cancer synergetic therapy.
- Authors: Zhang J, Shen B, Chen L, Chen L, Meng Y, Feng J
- Issue date: 2019 Mar 1
- Natural gelatin capped mesoporous silica nanoparticles for intracellular acid-triggered drug delivery.
- Authors: Zou Z, He D, He X, Wang K, Yang X, Qing Z, Zhou Q
- Issue date: 2013 Oct 15
- Amino-functionalized mesoporous silica nanoparticles as efficient carriers for anticancer drug delivery.
- Authors: He Y, Luo L, Liang S, Long M, Xu H
- Issue date: 2017 Oct
- Co-delivery of erlotinib and doxorubicin by pH-sensitive charge conversion nanocarrier for synergistic therapy.
- Authors: He Y, Su Z, Xue L, Xu H, Zhang C
- Issue date: 2016 May 10